JP2008511628A - α−２−アドレナリンアゴニスト成分を含有する組成物 - Google Patents

α−２−アドレナリンアゴニスト成分を含有する組成物 Download PDF

Info

Publication number
JP2008511628A
JP2008511628A JP2007530000A JP2007530000A JP2008511628A JP 2008511628 A JP2008511628 A JP 2008511628A JP 2007530000 A JP2007530000 A JP 2007530000A JP 2007530000 A JP2007530000 A JP 2007530000A JP 2008511628 A JP2008511628 A JP 2008511628A
Authority
JP
Japan
Prior art keywords
composition
component
preservative
adrenergic agonist
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008511628A5 (enExample
Inventor
リチャード・グレアム
ピーター・バキット
オレスト・オレジュニック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2008511628A publication Critical patent/JP2008511628A/ja
Publication of JP2008511628A5 publication Critical patent/JP2008511628A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007530000A 2004-08-27 2005-08-19 α−２−アドレナリンアゴニスト成分を含有する組成物 Pending JP2008511628A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/928,906 US20050026924A1 (en) 2000-07-14 2004-08-27 Compositions containing alpha-2-adrenergic agonist components
PCT/US2005/029707 WO2006026215A1 (en) 2004-08-27 2005-08-17 Compositions containing alpha-2-adrenergic agonist components

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012180411A Division JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Publications (2)

Publication Number Publication Date
JP2008511628A true JP2008511628A (ja) 2008-04-17
JP2008511628A5 JP2008511628A5 (enExample) 2008-10-02

Family

ID=35589384

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530000A Pending JP2008511628A (ja) 2004-08-27 2005-08-19 α−２−アドレナリンアゴニスト成分を含有する組成物
JP2012180411A Pending JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012180411A Pending JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Country Status (8)

Country Link
US (1) US20050026924A1 (enExample)
JP (2) JP2008511628A (enExample)
AU (1) AU2005280259A1 (enExample)
BR (1) BRPI0514723B8 (enExample)
CA (1) CA2578784C (enExample)
MX (1) MX2007002383A (enExample)
NZ (1) NZ599669A (enExample)
WO (1) WO2006026215A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019006776A (ja) * 2017-06-28 2019-01-17 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP2019104727A (ja) * 2017-12-08 2019-06-27 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP2020520891A (ja) * 2017-03-23 2020-07-16 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
WO2021065050A1 (ja) * 2019-09-30 2021-04-08 千寿製薬株式会社 水性液剤
JP2021054827A (ja) * 2019-09-30 2021-04-08 千寿製薬株式会社 水性液剤
JP2021152047A (ja) * 2020-11-18 2021-09-30 千寿製薬株式会社 水性液剤
JP7792540B2 (ja) 2025-03-10 2025-12-25 千寿製薬株式会社 水性液剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110251285A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
JP6730500B2 (ja) * 2018-10-01 2020-07-29 千寿製薬株式会社 水性液剤
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316441B1 (en) * 1998-12-17 2001-11-13 Alcon Manufacturing, Ltd. Brinzolamide and brimonidine for treating glaucoma
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002089804A1 (en) * 2001-05-03 2002-11-14 Allergan, Inc. Alpha-2-adrenergic agonist/fatty acid compositions
WO2003088973A1 (en) * 2002-04-19 2003-10-30 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4499077A (en) * 1981-02-03 1985-02-12 Stockel Richard F Anti-microbial compositions and associated methods for preparing the same and for the disinfecting of various objects
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JP3527256B2 (ja) * 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan, Inc. Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
SG44628A1 (en) * 1993-12-17 1997-12-19 Procter & Gamble 6-(2-imidazolinylamino) Quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5994110A (en) * 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
JP2004503593A (ja) * 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316441B1 (en) * 1998-12-17 2001-11-13 Alcon Manufacturing, Ltd. Brinzolamide and brimonidine for treating glaucoma
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002089804A1 (en) * 2001-05-03 2002-11-14 Allergan, Inc. Alpha-2-adrenergic agonist/fatty acid compositions
WO2003088973A1 (en) * 2002-04-19 2003-10-30 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520891A (ja) * 2017-03-23 2020-07-16 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
JP2024128161A (ja) * 2017-06-28 2024-09-20 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP7170436B2 (ja) 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP7767517B2 (ja) 2017-06-28 2025-11-11 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP2019006776A (ja) * 2017-06-28 2019-01-17 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP7524272B2 (ja) 2017-06-28 2024-07-29 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP2022190022A (ja) * 2017-06-28 2022-12-22 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP2019104727A (ja) * 2017-12-08 2019-06-27 千寿製薬株式会社 水溶性高分子を含む水性液剤
WO2021065050A1 (ja) * 2019-09-30 2021-04-08 千寿製薬株式会社 水性液剤
JP2021054735A (ja) * 2019-09-30 2021-04-08 千寿製薬株式会社 水性液剤
JP2021054827A (ja) * 2019-09-30 2021-04-08 千寿製薬株式会社 水性液剤
JP2022036159A (ja) * 2020-11-18 2022-03-04 千寿製薬株式会社 水性液剤
JP7002692B2 (ja) 2020-11-18 2022-02-04 千寿製薬株式会社 水性液剤
JP7447072B2 (ja) 2020-11-18 2024-03-11 千寿製薬株式会社 水性液剤
JP2024052871A (ja) * 2020-11-18 2024-04-12 千寿製薬株式会社 水性液剤
JP2021152047A (ja) * 2020-11-18 2021-09-30 千寿製薬株式会社 水性液剤
JP2025078837A (ja) * 2020-11-18 2025-05-20 千寿製薬株式会社 水性液剤
JP2025172217A (ja) * 2020-11-18 2025-11-20 千寿製薬株式会社 水性液剤
JP7792540B2 (ja) 2025-03-10 2025-12-25 千寿製薬株式会社 水性液剤

Also Published As

Publication number Publication date
BRPI0514723A8 (pt) 2018-05-08
JP2012246304A (ja) 2012-12-13
BRPI0514723B8 (pt) 2021-05-25
WO2006026215A1 (en) 2006-03-09
AU2005280259A1 (en) 2006-03-09
BRPI0514723B1 (pt) 2020-12-22
CA2578784A1 (en) 2006-03-09
NZ599669A (en) 2013-11-29
US20050026924A1 (en) 2005-02-03
BRPI0514723A (pt) 2008-06-24
CA2578784C (en) 2015-02-17
MX2007002383A (es) 2007-05-15

Similar Documents

Publication Publication Date Title
JP4927298B2 (ja) α−２−アドレナリンアゴニスト成分を含有する組成物
JP2012246304A (ja) α−２−アドレナリンアゴニスト成分を含有する組成物
AU2001273269A1 (en) Compositions containing alpha-2-adrenergic agonist components
JP2004503593A (ja) 増大した溶解度を持つ治療活性成分を含む組成物
JP2010132681A (ja) 向上した薬物動態特性を有する組成物
US10307368B2 (en) Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) Compositions containing alpha-2-adrenergic agonist components
US20040219219A1 (en) Compositions containing alpha-2-adrenergic agonist components
AU2011250793B2 (en) Compositions containing alpha-2-adrenergic agonist components
JP2004528369A (ja) 向上した薬物動態特性を有する組成物
CA2474280C (en) Compositions containing alpha-2-adrenergic agonist components
AU2007202599B2 (en) Compositions containing alpha-2-adrenergic agonist components
HK1060519B (en) Compositions containing alpha-2-adrenergic agonist components

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120816